Gongtong Pharmaceutical released its 2026 interim report. Total operating revenue was 346 million yuan, and net profit attributable to the parent company was a loss of 32.84 million yuan, an increase in loss of 21.69 million yuan compared with the same period last year. Net cash inflow from operating activities was 22.48 million yuan. The company's asset-liability ratio was 69.96%, gross margin was 14.08%, ROE was negative 4.13%, and diluted earnings per share was negative 0.29 yuan. The number of shareholders was 11,500, and the top ten shareholders held 54.78% of the total share capital.
Hubei Goto Biopharm Co.Ltd.Net loss widened by 21.69 million yuan year-over-year.